Loading...
•
Mar 31, 2023
Immunic Q1 2023 Earnings Report
Announced first quarter 2023 financial results and provided a corporate update, highlighting positive results from the Phase 1b clinical trial of IMU-856 in celiac disease and progress in the Phase 2 CALLIPER trial of Vidofludimus Calcium in progressive multiple sclerosis.
Key Takeaways
Immunic reported positive results from the Phase 1b clinical trial of IMU-856 in celiac disease, demonstrating improvements in histology, disease symptoms, biomarkers, and nutrient absorption. The company is preparing for a Phase 2b clinical trial of IMU-856 in celiac disease patients. Additionally, data from the maintenance phase of the Phase 2b CALDOSE-1 trial of vidofludimus calcium in ulcerative colitis showed statistically significant activity compared to placebo. The company expects an interim biomarker analysis from the Phase 2 CALLIPER trial of vidofludimus calcium in progressive MS in the second half of 2023.
Reported positive data from the maintenance phase of the phase 2b CALDOSE-1 trial of vidofludimus calcium in patients with moderate-to-severe ulcerative colitis (UC).
Announced positive results from our phase 1b clinical trial of IMU-856 in patients with celiac disease.
Preparing for a phase 2b clinical trial of IMU-856 in ongoing active celiac disease patients.
Next value inflection point will be a second half 2023 interim biomarker analysis of our phase 2 CALLIPER trial in progressive MS.
Forward Guidance
Immunic expects its cash, cash equivalents and investments to fund operations into the fourth quarter of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...